Trial Profile
An Open-label Study of Xeloda Plus Taxotere on Treatment Response in Patients With HER2-neu-negative, and the Addition of Herceptin for HER2-neu-positive Breast Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Capecitabine; Docetaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms XeNA
- 01 Sep 2009 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
- 21 Aug 2009 Status changed from active, no longer recruiting to completed as reported by Roche.
- 21 Aug 2009 Status changed from active, no longer recruiting to completed as reported by Roche.